Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 413 Print this page  Email this page Small font size Default font size Increase font size


 
 Table of Contents     
LETTER TO THE EDITOR
Year : 2019  |  Volume : 34  |  Issue : 1  |  Page : 76-77  

Alpha therapy with 225Actinium labeled prostate specific membrane antigen: Reporting new photopeak of 78 kilo-electron volts for better image statistics


1 Department of Chemistry, Government College University, Faisalabad, Pakistan
2 Kuwait Cancer Control Center, Shuwaikh, Kuwait City, Kuwait
3 Jabber Al-Ahmad Centre for Molecular Imaging, Kuwait City, Kuwait

Date of Web Publication17-Jan-2019

Correspondence Address:
Dr. Rashid Rasheed
Department of Chemistry, Government College University, Kotwali Road, Faisalabad 38000
Pakistan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijnm.IJNM_115_18

Rights and Permissions

How to cite this article:
Rasheed R, Usmani S, Raza Naqvi SA, Alkandari F, Marafi F. Alpha therapy with 225Actinium labeled prostate specific membrane antigen: Reporting new photopeak of 78 kilo-electron volts for better image statistics. Indian J Nucl Med 2019;34:76-7

How to cite this URL:
Rasheed R, Usmani S, Raza Naqvi SA, Alkandari F, Marafi F. Alpha therapy with 225Actinium labeled prostate specific membrane antigen: Reporting new photopeak of 78 kilo-electron volts for better image statistics. Indian J Nucl Med [serial online] 2019 [cited 2019 Feb 16];34:76-7. Available from: http://www.ijnm.in/text.asp?2019/34/1/76/250353



Sir,

Recent work has shown that Alpha-emitting radioisotope Actinium-225 (225 Ac) appears more effective than other radionuclides due to better half-life and targeted radiolabeling.[1],[2] Limited imaging data are available on the posttherapy imaging using 225 Ac labeled prostate-specific membrane antigen (225 Ac-PSMA) radioligand therapy in metastatic castration-resistant prostate cancer.[3] The count rate or imaging statistics can be used to enhance the image quality in posttherapy 225 Ac images to have a better image contrast for assessment of tracer localization in the target/metastatic lesions. Moreover, high image count rate is also helpful in dosimetry calculations and assessment of in-vivo biodistribution. Current literature suggests clinical imaging using two photopeaks 440 kilo-electron volts (KeV) (26.5% of 213 Bi decays to give 440 KeV) and 218 KeV during 225 Ac-PSMA therapy.[4] However, during our initial study of 225 Ac gamma-ray spectrum, it was noted that 225 Ac has a third notable photopeak of 78 KeV [Figure 1], which shows higher share of photon abundance then the rest of the photopeaks, that is, 440 KeV and 218 KeV. The effective imaging potential of each peak was studied with hot-rod phantom [Figure 2] using medium energy collimator as per recommendations for 225 Ac quality control. The results showed that 78 KeV peaks have significant count statistics for imaging [Figure 2]b when compared to prior recommended photopeaks as shown in [Figure 2]c. The images acquired with addition of 78 kev photo peak has better count statistics then the images taken with only two photo peaks of 440 KeV and 218 KeV. The technetium-99m phantom images were also acquired, as for exemplary image of high counts for visual comparison with 225 Ac images as shown in [Figure 2]a.
Figure 1: Gamma ray spectrum of 225Ac labeled prostate specific membrane antigen-617 showing multiple photo peaks in red. (A) Photo peak of 77.94 kilo electron volts, (B) Photo peak of 218 kilo electron volts in yellow box, (C) Photo peak of 440 kilo electron volts yellow box, (D) Bremsstrahlung peak (very low abundance which is not suitable for imaging). Currently, the literature recommends 225Ac imaging using two photo peaks, that is, 440 kilo electron volts and 218 kilo electron volts. However, it is appreciable that there is a third significant peak of 77.9 kilo electron volts which has a significant count density

Click here to view
Figure 2: Phantom study of 225Ac labeled prostate specific membrane antigen-617 showing magnitude and count density of each photo peak. (a) reference Technetium flood showing good count statistics and good image resolution at 140 kilo electron volts, (b) Phantom image with single photo peak of 77.9 kilo electron volts showing significant count density to be used in future actinium-225 imaging, (c) Phantom imaging with two photo peaks (218 kilo electron volts and 440 kilo electron volts), (d) Phantom image showing image of all three photo peaks (77.9 kilo electron volts + 218 kilo electron volts and 440 kilo electron volts)

Click here to view


Posttherapy images are a potential source of quality control to confirm the localization of 225 Ac-PSMA-617 in the target metastatic sites; therefore, posttherapy imaging has vital place in the management of cancer patients, especially to differentiate posttherapy flare from other possible systemic adverse effects after radionuclide therapy and to calculate organ dosimetry wherever required. It is, therefore, suggested that photopeak of 78 KeV may be included in the imaging of 225 Ac-PSMA-617 therapy to get better image quality and to perform better statistical analysis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm 2011;4:306-20.  Back to cited text no. 1
    
2.
Kassis AI. Therapeutic radionuclides: Biophysical and radiobiologic principles. Semin Nucl Med 2008;38:358-66.  Back to cited text no. 2
    
3.
Allen BJ. Targeted alpha therapy: Evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas Radiol 1999;43:480-6.  Back to cited text no. 3
    
4.
Wadas TJ, Pandya DN, Solingapuram Sai KK, Mintz A. Molecular targeted α-particle therapy for oncologic applications. AJR Am J Roentgenol 2014;203:253-60.  Back to cited text no. 4
    


    Figures

  [Figure 1], [Figure 2]



 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References
    Article Figures

 Article Access Statistics
    Viewed47    
    Printed0    
    Emailed0    
    PDF Downloaded23    
    Comments [Add]    

Recommend this journal